Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
N-glycosylation in the SERPIN domain of the C1-esterase inhibitor in hereditary angioedema
Zhen Ren, John Bao, Shuangxia Zhao, Nicola Pozzi, H. James Wedner, John P. Atkinson
Zhen Ren, John Bao, Shuangxia Zhao, Nicola Pozzi, H. James Wedner, John P. Atkinson
View: Text | PDF
Research Article Immunology

N-glycosylation in the SERPIN domain of the C1-esterase inhibitor in hereditary angioedema

  • Text
  • PDF
Abstract

Hereditary angioedema is an autosomal dominant disorder caused by defects in C1-esterase inhibitor (C1-INH), resulting in poorly controlled activation of the kallikrein-kinin system and bradykinin overproduction. C1-INH is a heavily glycosylated protein in the serine protease inhibitor (SERPIN) family, yet the role of these glycosylation sites remains unclear. To elucidate the functional impact of N-glycosylation in the SERPIN domain of C1-INH, we engineered 4 sets consisting of 26 variants at or near the N-linked sequon (NXS/T). Among these, 6 are reported in patients with hereditary angioedema and 5 are known C1-INH variants without accessible clinical histories. We systematically evaluated their expression, structure, and functional activity with C1s̄, FXIIa, and kallikrein. Our findings showed that of the 11 reported variants, 7 were deleterious. Deleting N at the 3 naturally occurring N-linked sequons (N238, N253, and N352) resulted in pathologic consequences. Altering these sites by substituting N with A disrupted N-linked sugar attachment, but preserved protein expression and function. Furthermore, an additional N-linked sugar generated at N272 impaired C1-INH function. These findings highlight the importance of N-linked sequons in modulating the expression and function of C1-INH. Insights gained from identifying the pathological consequences of N-glycan variants should assist in defining more tailored therapy.

Authors

Zhen Ren, John Bao, Shuangxia Zhao, Nicola Pozzi, H. James Wedner, John P. Atkinson

×

Figure 6

N253 glycosylation site variants.

Options: View larger image (or click on image) Download as PowerPoint
N253 glycosylation site variants.
(A) WB analysis of supernatants from t...
(A) WB analysis of supernatants from transfected WT and N253 variant constructs under reducing conditions. Recombinant expression of N253 variants was comparable to WT (see Table 1). N253A, N253del, N254del, and S255G disrupt the N-glycan attachment and lead to a slightly lower Mr protein compared with WT. The consensus sequence of N253 glycosylation (NXS/T) is highlighted in blue, orange, and red. It contains 2 Ns in this sequence. (B) WB analysis of variants N254del and S255G before and after treatment with glycosidases. Recombinant expression of N254del and S255G was comparable to WT, but with a slightly lower Mr compared with WT (lane 1). After deglycosylation, WB demonstrated that N254del (lane 8), S255G (lane 9), and WT have the same Mr. Δ, post-degylcosylation. (C–F) Functional analysis of the N253 glycosylation site variants. (C and E) Absorbance is plotted against protein concentrations. (D and F) Binding affinity of N253 glycosylation site variants for PKa and FXIIa compared with WT. The binding affinity of N253A, N254A, S255del, S255G, and S255T for PKa and FXIIa was comparable to WT. N253del and N254del exhibited mildly impaired binding to PKa and FXIIa. Results shown are from 3 independent experiments. Data represent mean ± SEM. *P <0.05, ***P < 0.001, ****P < 0.0001 by 1-way ANOVA and Dunnett’s multiple-comparison test. (G) Structural analysis of N253. The structure of active C1-INH is shown in a cartoon representation (PDB: 5DU3). N253 is located in the loop connecting strand 1 in β-sheet A (S1A) and helix F (hF).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts